Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2 Breast Cancer

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Dr. Freedman on Neratinib Plus Capecitabine for CNS Disease from HER2-Positive Breast CancerПодробнее

Neratinib + Capecitabine in HER2+ Breast CancerПодробнее

Pyrotinib Plus Capecitabine for HER2 Metastatic Breast CancerПодробнее

HER2+ De Novo MBC: Neratinib Vs Lapatinib Plus CapecitabineПодробнее

Dr. Jagielska on Long-Term Survival With Lapatinib Plus Capecitabine in HER2+ Breast CancerПодробнее

Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain MetastasesПодробнее

Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain MetastasesПодробнее

Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trialsПодробнее

Adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in HER2-positive breast cancerПодробнее

Study of Neratinib for Patients with HER2-Positive Breast Cancer with Brain MetastasesПодробнее

Dr. Nye on Neratinib-Associated Diarrhea in HER2+ Breast CancerПодробнее

A Study of Brain Radiotherapy With Lapatinib in HER2+ Breast CancerПодробнее

Neratinib in HER2+ Breast CancerПодробнее

Metastatic Breast Cancer Forum 2018: HER2-positive Breast Cancer | Dana-Farber Cancer InstituteПодробнее

R/R HER2+ mBC: Interpreting Findings From the NALA TrialПодробнее

ELEANOR: real-world use of neratinib in HER2+, early breast cancerПодробнее

Systemic Therapies Shown to be Effective in HER2-Positive Breast CancerПодробнее

Neratinib for Metastatic Breast CancerПодробнее